✦ LIBER ✦

Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study

✍ Scribed by Changsu Han; David M. Marks; Chi-Un Pae; Bun Hee Lee; Young-Hoop Ko; Prakash S. Masand; Ashwin A. Patkar; In-Kwa Jung

Book ID: 116396325
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 595 KB
Volume: 69
Category: Article
ISSN: 0011-393X
DOI: 10.1016/j.curtheres.2008.06.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluoxetine versus sertraline in the trea

Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial

✍ Changsu Han; Chi-Un Pae; Bun Hee Lee; Young-Hoon Ko; Prakash S. Masand; Ashwin A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Reboxetine augmentation of fluoxetine fo

Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study

✍ Rapaport, M.; Wilcox, C.; Heiser, J.; Londborg, P.; Schwartz, G. 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Olanzapine monotherapy for acute depress

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial

✍ William V. Bobo; Richard A. Epstein; Richard C. Shelton 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open‐label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery–Asb

Ustekinumab for the treatment of patient

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

✍ Poddubnyy, D.; Hermann, K.-G. A.; Callhoff, J.; Listing, J.; Sieper, J. 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 929 KB